Top Markets
#1 Purr Purr +62.46%
#2 Pons Pons +55.25%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 TENDIES TENDIES +39.28%
#5 Non-Playable Coin Non-Playable Coin +34.62%
#6 Morpho Morpho +27.07%
#7 Cash Cat Cash Cat +26.52%
#8 Kinetiq Kinetiq +24.33%
#9 StonkBroker StonkBroker +23.38%
#10 Grass Grass +20.89%
Coin of the day
Purr Purr
設定
言語
日本
通貨
USD
テーマ
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
株式のランク #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
株価
$1.54
最終同期: 2024-04-08
時価総額
$119.21M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 NGM Biopharmaceuticals, Inc. (NGM)

カテゴリー

Healthcare
NGM Biopharmaceuticals, Inc.（NGM）の株価履歴
終値の最高値: $1.55 （2024-04-01）

終値の最安値: $15.78 （2019-04-01）
NGM Biopharmaceuticals, Inc. の株価履歴（2019 ～ 2026）
年間株価パフォーマンス
年 パフォーマンス
2024 86.99%
2023 -84.01%
2022 -71.29%
2021 -34.64%
2020 51.84%
2019 0.00%
類似企業または競合の株価
企業 株価 変化率 1年% 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.71 38.62%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 58.06%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $145.75 437.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $118.70 -15.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $770.19 8.98%
CH